Shares of Genenta Science S.p.A. (NASDAQ:GNTA - Get Free Report) were down 1.3% during trading on Friday . The company traded as low as $3.51 and last traded at $3.76. Approximately 22,483 shares changed hands during trading, an increase of 43% from the average daily volume of 15,753 shares. The stock had previously closed at $3.81.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a "buy" rating and set a $25.00 target price on shares of Genenta Science in a research note on Wednesday, October 2nd.
Check Out Our Latest Stock Analysis on GNTA
Genenta Science Stock Down 1.3 %
The business's 50 day moving average price is $4.88 and its 200-day moving average price is $4.56.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Genenta Science stock. AlTi Global Inc. acquired a new position in shares of Genenta Science S.p.A. (NASDAQ:GNTA - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 200,288 shares of the company's stock, valued at approximately $621,000. AlTi Global Inc. owned about 1.10% of Genenta Science at the end of the most recent quarter. 15.13% of the stock is owned by institutional investors.
Genenta Science Company Profile
(
Get Free Report)
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
Further Reading
Before you consider Genenta Science, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genenta Science wasn't on the list.
While Genenta Science currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
